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Abstract
Background: Anxiety and depression are in both cross-sectional and longitudinal studies associated with urinary
incontinence (UI) in women, strongest for the urgency component of UI. The role of psychotropic drugs in this
association, especially antidepressants, has been questioned, but not clarified. The present study aimed to explore the
associations between UI and anxiety/depression and the possible impact of psychotropic drugs on these associations.
Methods: We conducted a cross-sectional, population-based study with questionnaire data from 21,803 women ≥20
years in the Norwegian Nord-Trøndelag Health Study merged with the Norwegian Prescription Database, which contains
information on all dispensed prescriptions. We used multivariate logistic regression to investigate the association between
UI (any UI, and by type and severity) and anxiety/depression (by different score on Hospital anxiety and depression scale),
and the influence of psychotropic drugs on this association (by different volume of drug use).
Results: Compared with normal anxiety- and depression score, having moderate/severe anxiety or depression (HADS≥11)
increased the prevalence of UI from 27.6 to 37.8% (OR 1.59 (1.40–1.81), p < 0.001) for anxiety and from 28.0 to 43.7% (OR
1.79 (1.46–2.21), p < 0.001) for depression. According to type of UI, mixed UI was most strongly associated with a high
HADS-score with an odds ratio 1.84 (1.65–2.05) for anxiety and 1.85 (1.61–2.13) for depression. Compared to no UI, severe
UI was associated with depression with odds ratios of 2.04 (1.74–2.40), compared with no UI. Psychotropic drug use did
not influence the associations between UI and anxiety/depression. We found high prevalence of UI among users of
various psychotropic drugs. After adjustments, only antidepressants were associated with UI, with OR 1.36 (1.08–1.71) for
high defined daily dose of the drug. Anxiolytics were associated with less UI with OR 0.64 (0.45–0.91) after adjustments for
anxiety.
Conclusion: This study showed that anxiety, depression and use of antidepressants are associated factors with UI,
strongest for urgency and mixed type of UI, with increasing ORs by increasing severity of the conditions and increased
daily dose of the medication. Use of antidepressants did not influence the associations between UI and anxiety/
depression.
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Background
Depression and anxiety are in cross-sectional studies asso-
ciated with higher prevalence of urinary incontinence (UI)
in women [1–4]. According to type, studies show an asso-
ciation to all three main types of UI, but strongest for ur-
gency and mixed UI [3, 5]. In three longitudinal studies,
depression at baseline predicted onset of UI [6–8].
The serotonergic and noradrenergic systems are in-
volved in both bladder control and in the pathology of
depression/anxiety. Antidepressants affecting this neuro-
hormonal system are the leading pharmacological inter-
vention for mood- and anxiety disorders [9–11], but the
antidepressant duloxetine has also documented effect as
treatment for stress UI [12, 13]. Beside being a treatment
for UI, several studies have also shown an association
between the use of antidepressants and high prevalence
of UI, strongest for mixed and urgency UI [14–16]. It is
unknown whether confounding by indication can ex-
plain this association, or whether antidepressants induce
UI through biological mechanisms.
In the present cross-sectional study, the aim was firstly
to investigate the associations between UI and anxiety/
depression and psychotropic drug use for different sever-
ity of the conditions and for different volume of drug
use. Secondly, we aimed to investigate if the associations
between UI and anxiety/depression for the possible im-
pact of psychotropic medication use.
Methods
In this cross-sectional study we used data from the third
wave of The Nord-Trøndelag Health Study (HUNT3)
and the Norwegian Prescription Database (NorPD).
HUNT3 (2006–08) was a population-based survey in-
viting all persons ≥20 years in the former county of
Nord-Trøndelag (n = 47,293 women) [17], which is now
part of the county Trøndelag. The survey included ques-
tions covering a broad specter of medical conditions.
Together with an invitation by post, the participants re-
ceived a questionnaire (Q1), which they brought to a
screening station where they underwent clinical exami-
nations and blood tests. The women received another
questionnaire (Q2) at the screening station, which they
filled in at home and returned by mail. Q2 included
questions about anxiety, depression, and UI. A total of
27,692 (59%) women answered Q1 and received Q2
(source population). 23,141 women answered Q2 and
21,803 (79%) of these answered the UI-part of the ques-
tionnaire (study population).
Assessment of urinary incontinence
The EPINCONT study (Epidemiology of Incontinence
in Nord-Trøndelag) is the UI part of the HUNT surveys
[18]. We define UI as any leakage of urine [19]. If the
participant answered yes on the entry question if she
had experienced urine leakage, she was asked more spe-
cific questions about frequency (four levels), amount
(three levels) and in which situations she experienced
the leakage. Those who, despite answering “no” or failing
to answer the entry question, answered confirmatively
on the specific questions, were also regarded as answer-
ing “yes” on the entry question. Those not answering the
entry question about leaking urine and answered two or
less of the following three questions, where classified as
missing (n = 40). A stress component was defined if the
participant leaked urine when coughing, laughing, sneez-
ing, or making an effort. If she had leakage in conjunc-
tion with urgency to void, we defined an urgency
component. If answering “yes” on both these questions,
we defined the leakage as mixed UI. Those who an-
swered “no” on both the urgency and stress UI question,
despite answering “yes” on the entry question about loss
of urine, were grouped as unclassified. We used the
four-level Sandvik severity index to categorize the sever-
ity of the UI [20, 21]: the reported frequency was multi-
plied by the amount of leakage, resulting in an index
value (1–12), further categorized into three or four se-
verity levels. In our analysis three levels were used.
Assessment of depression and anxiety
High score on the Hospital Anxiety and Depression
Scale, HADS-A and HADS-D, defined anxiety and de-
pression, respectively [22–25]. HADS is a self-
administered questionnaire with seven questions for
anxiety (HADS-A) and seven for depression (HADS-D).
Each item has four possible answers, scored on a Likert
scale from zero to three, giving subscales from 0 to 21
when added. Zero is minimum and 21 is maximum
symptom level on separate scales for anxiety and depres-
sion. A substitution of missing data was performed for
persons who responded to five or six of the HADS-A
and HADS-D questions by assuming similar responses
on the questions not answered as in those answered
(n = 966). When from one to four questions were an-
swered, the score was regarded as missing (n = 319).
HADS-A and HADS-D score of eight or more defined
clinically significant anxiety and depression, respectively.
We defined mild anxiety and depression by score 8- < 11
and moderate/severe anxiety and depression by score ≥
11 on the HADS-A and HADS-D-scale, respectively.
Assessment of psychotropic medication use
The NorPD is a national health register containing infor-
mation about all prescriptions dispensed at Norwegian
pharmacies. Each time a drug is dispensed, the generic
name, Anatomical Therapeutic Chemical (ATC)- code,
strength, number of packages and defined daily dose
(DDD) are registered. DDD is the average maintenance
dose per day for a drug used for its main indication in
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adults. The DDD reflects the total amount of drug pre-
scribed and dispensed, and the overall amount of the ac-
tual drug during the last 6months was calculated. We
defined drug use as dispensed prescription during the last
6months. In the dose-response analysis, we used four dif-
ferent degrees of DDD: no use, low DDD, medium DDD
and high DDD. The cut-offs were set separately for each
drug, due to different user profiles. The following drug
groups were used in the analyses: Opioid analgesics
(ATC-code: N02A), other analgesics (N02B), antiepileptic
drugs (N03), lamotrigine (N03A X09), antiparkinson
drugs (N04), antipsychotics (N05A), anxiolytics (N05B),
hypnotics and sedatives (N05c), antidepressants (N06A)
and selective serotonine reuptake inhibitors (SSRIs)
(N06AB), urologics (G04BD), estrogens (G03C) and pro-
gesterons and estrogens in combination (G03F). We se-
lected drug groups due to literature indicating possible
association with UI [13–16, 26–28].
Variables selected from HUNT3 and NorPD were
linked, using the identification number assigned to
everyone living in Norway.
Statistical analyses
Level of statistical significance was set at 5%. SPSS ver-
sion 25 was used for analyses. We used descriptive sta-
tistics to characterize the study group regarding UI,
anxiety, depression, and medication use.
We used multivariate logistic regression with anxiety
and depression as dependent variables to investigate the
association between anxiety and UI and depression and
UI, respectively, including by different types and severity
of UI. To investigate the possible effect modification of
psychotropic drug use on anxiety and depression, we used
two logistic regression models with UI as dependent vari-
able in both. In the first model, use of different psycho-
tropic drugs by DDD groups were independent variables
together with depression. In the other model, use of psy-
chotropic drugs by DDD groups were independent vari-
ables together with anxiety. Secondly, we analyzed the
prevalence and ORs of UI in groups of individuals with
anxiety and depression, comparing users and non-users of
antidepressants and anxiolytics. In all the logistic regres-
sion analyses, we adjusted for the following potential con-
founders and risk factors: age, BMI, parity, diabetes,
asthma, myocardial infarction, cerebral stroke, chronic
pain, rheumatoid arthritis, use of urologic medication for
urgency, and use of estrogen replacement medication. The
adjustment variables were chosen based on pre-specified
known risk factors and medication with possible impact
on UI prevalence [16, 29].
Results
The mean age of women was 53 years, 61% were over-
weight (BMI 25.0–29.9) or obese (BMI ≥ 30), mean
number of children was 2.1. Characteristics regarding
UI, anxiety, depression, and medication use are shown
in Table 1. 29% of the women met the definition of UI,
23% in the youngest group (19–39 years), 32% in the
oldest group (≥55 years). Stress UI was most common
type in the two youngest age groups (up to 54 years),
mixed was most common in the oldest group. 12% of all
women with UI had severe or very severe UI, 19% in the
oldest group.
6% met the definition of mild depression, while 2%
had moderate/severe depression. In those two groups,
21 and 35% used an antidepressant drug, respectively.
11% had mild anxiety and 6% moderate/severe anxiety.
In these groups the use of antidepressant drugs was 16
and 30%, respectively. 9% of all women used antidepres-
sants, 11% in the oldest age group. 60% of the anti-
depressant users used a SSRI. 10% used hypnotics and
sedatives, 17% among the oldest. 5% used an anxiolytic.
Anxiety and depression were both associated with UI,
with ORs 1.48 (1.36–1.60) and 1.58 (1.42–1.76), respect-
ively, when adjusted for known confounders and risk fac-
tors for UI. Both anxiety and depression were strongest
associated with mixed and severe UI. Depression was asso-
ciated with severe UI, with OR 2.04 (1.74–2.40) (Table 2).
The following psychotropic drug groups were associ-
ated with UI in the unadjusted analyses, also with a
dose-dependent trend (not shown in tables): antidepres-
sants generally, SSRIs, opioid and other analgesics and
antiparkinson drugs. Antipsychotics and hypnotics were
associated, without any dose-dependent trend. Anxio-
lytic or antiepileptic drugs in general were not associated
with UI, but the antiepileptic drug lamotrigine was asso-
ciated with UI, although not in a dose-dependent man-
ner. Table 3 shows the results of two logistic regression
models with UI as dependent factor, and anxiety and de-
pression as independent factors, respectively. The results
demonstrate the influence of psychotropic drugs on the
association between anxiety and UI and depression and
UI. After adjusting for all psychotropic drugs, the OR
for UI for persons with anxiety did not change com-
pared to only adjusting for the other confounders and
risk factors. However, medium and high volume of
antidepressants and high volume of antiparkinson
drugs were associated with UI. Use of high volume of
anxiolytics and medium volume of hypnotics/sedatives
were negatively associated with UI. After adjustments
for all psychotropic drugs, depression was associated
with UI with OR 1.55 (1.39–1.73), compared with OR
1.58 (1.42–1.76) when only adjusting for the other
confounders and risk factors. Also, in these analyses
medium and high volume of antidepressants were as-
sociated with UI. High volumes of anxiolytics and
medium volumes of hypnotics/sedatives were nega-
tively associated.
Felde et al. BMC Psychiatry          (2020) 20:521 Page 3 of 10
Table 1 Characteristics of the study population (N = 21,803), by age groups
Age at inclusion
(years)









N % N % N % N %
Parity a
None 1577 32.1 402 6.0 643 6.3 2622 12.0
1 712 14.5 645 9.6 733 7.2 2090 9.6
2 1565 31.8 2770 41.2 3296 32.4 7631 35.0
≥ 3 1050 21.4 2895 43.0 5472 53.9 9417 43.2
Body mass index a
< 18.5 (underweight) 72 1.5 40 0.6 70 0.7 182 0.8
18.5–24.9 (normal) 2515 51.2 2707 40.2 2991 29.4 8213 37.8
25.0–29.9 (overweight) 1434 29.2 2579 38.3 4245 41.8 8258 38.0
≥ 30 (obesity) 879 17.9 1387 20.6 2806 27.6 5072 23.3
Asthma 668 13.6 752 11.2 1211 11.9 2631 12.1
Myocardial infarction 1 0 24 0.4 312 3.1 337 1.5
Cerebral stroke 11 0.2 72 1.1 424 4.2 507 2.3
Diabetes 47 1.0 137 2.0 672 6.6 856 3.9
Continence status a
Continent 3800 77.3 4735 70.4 6936 68.3 15,471 71.0
Any UI 1116 22.7 1991 29.6 3225 31.7 6332 29.0
Type of UI (n = 6332) a
Stress 613 54.9 1015 50.9 1068 33.2 2696 42.6
Urgency 136 12.2 213 10.7 524 16.2 873 13.8
Mixed 296 26.5 705 35.4 1471 45.6 2472 39.0
Other/unclassified 68 6.1 51 2.6 132 4.1 251 4.0
Missing 3 0.3 7 0.4 30 0.9 40 0.6
Severity of UI (n = 6332) a
Slight 664 59.5 959 48.2 952 29.5 2575 40.7
Moderate 398 35.7 888 44.6 1498 46.4 2784 44.0
Severe 33 3.0 89 4.5 522 16.2 644 10.2
Very severe 1 0.1 14 0.7 101 3.1 116 1,8
Missing 20 1.8 41 2.1 152 4.7 213 3.4
Anxiety
HADS-A 8–10.9 569 11.6 714 10.6 1106 10.9 2389 11.0
Antidepressant status (n = 2389) a
Using 62 10.9 114 16.0 211 19.1 387 16.2
Not using 507 89.1 600 84.0 895 80.9 2002 83.8
HADS-A ≥ 11 311 6.3 442 6.6 563 5.5 1316 6.0
Antidepressant status (n = 1316) a
Using 62 19.9 130 29.4 197 35.0 389 29.6
Not using 249 80.1 312 70.6 366 65.0 927 70.4
Depression
HADS-D 8–10.9 215 4.4 377 5.6 839 8.3 1431 6.6
Antidepressant status (n = 1431) a
Using 32 14.9 94 24.9 178 21.2 304 21.2
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Table 4 shows the prevalence of UI and odds ratios for
UI for women with increasing HADS-A- and HADS-D-
score and for women with high HADS-scores using anti-
depressants or anxiolytics compared with non-users. For
persons with no anxiety, mild, or moderate/severe anx-
iety, the prevalence of UI was 28, 35 and 39%, respect-
ively. For persons with anxiety using antidepressants, the
prevalence of UI was 41%, not significant after adjust-
ments, when compared to the women with anxiety not
using antidepressants, OR 1.11 (0.93–1.34). For persons
with anxiety, using anxiolytics was associated with a
small, but significant decrease in UI, OR 0,80 (0,64-0,
99). The same decrease in OR was present among de-
pressed women using an anxiolytic, but with lack of
Table 1 Characteristics of the study population (N = 21,803), by age groups (Continued)
Age at inclusion
(years)









N % N % N % N %
Not using 183 85.1 283 75.1 661 78.8 1127 78.8
HADS-D ≥ 11 60 1.2 146 2.2 240 2.4 446 2.0
Antidepressant status (n = 446)) a
Using 21 35.0 49 33.6 85 35.4 155 34.8
Not using 39 65.0 97 66.4 155 64.6 291 65.2
Psychotropic drug use b
Opioid analgesics 245 5.0 540 8.0 912 9.0 1697 7.8
Non-opioid analgesics 136 2.8 385 5.7 891 8.8 1412 6.5
Anti-epileptics 47 1.0 133 2.0 213 2.1 393 1.8
Lamotrigin 21 0.4 26 0.4 35 0.3 82 0.4
Anti-parkinson drug 1 0 7 0.1 87 0.9 95 0.4
Anti-psychotics 34 0.7 107 1.6 238 2.3 379 1.7
Anxiolytics 72 1.5 283 4.2 817 8.0 1172 5.4
Hypnotics/sedatives 91 1.9 391 5.8 1693 16.7 2175 10.0
Anti-depressants (all) 234 4.8 588 8.7 1125 11.1 1947 8.9
SSRI 163 3.3 358 5.3 653 6.4 1174 5.4
UI Urinary incontinence
HADS Hospital anxiety and depression scale
SSRI selective serotonin receptor inhibitor
aColumn-distribution
b Drug use was defined as dispensed prescription last 6 months
Table 2 Odd ratios (ORs) for anxiety (HADS-A≥ 8) and depression (HADS-D ≥ 8) for women with any urinary incontinence (UI),
different types and severities of UI versus continence. N = 21,803
Anxiety Depression
Unadjusted OR Adjusted* OR Unadjusted OR Adjusted* OR
Continence 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Any UI 1.46 (1.35–1.57) 1.48 (1.36–1.60) 1.74 (1.58–1.92) 1.58 (1.42–1.76)
Severity of UI
Slight 1.29 (1.16–1.44) 1.31 (1.17–1.47) 1.14 (0.97–1.32) 1.17 (1.00–1.38)
Moderate 1.48 (1.31–1.66) 1.52 (1.34–1.72) 1.78 (1.53–2.07) 1.67 (1.42–1.96)
Severe 1.69 (1.50–1.91) 1.74 (1.52–1.99) 2.61 (2.26–3.00) 2.04 (1.74–2.40)
Type of UI
Stress 1.24 (1.11–1.37) 1.27 (1.13–1.42) 1.37 (1.19–1.58) 1.38 (1.18–1.60)
Urgency 1.32 (1.11–1.58) 1.44 (1.20–1.73) 1.78 (1.44–2.20) 1.50 (1.19–1.90)
Mixed 1.84 (1.66–2.03) 1.84 (1.65–2.05) 2.17 (1.91–2.46) 1.85 (1.61–2.13)
* Adjusted for age, BMI, parity, diabetes, asthma, myocardial infarction, cerebral stroke, chronic pain, rheumatoid arthritis, use of urologic medication and use of
estrogen replacement medication
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statistical significance. For persons with no depression,
mild, or moderate/severe depression the prevalence of
UI increased from 28, to 39% and 44%, respectively, but
there was no additional increase in prevalence in the de-
pressed group using antidepressants.
Discussion
In this large population-based study, high levels of anx-
iety and depression were associated with UI, strongest
for mixed and severe UI. The prevalence of UI was
higher among users of several psychotropics compared
to non-users. After adjustments, antidepressants were
still associated with UI. However, the associations be-
tween anxiety/depression and UI were not influenced by
use of psychotropic drugs in the present study.
The strengths of the study include a large sample size,
a good response rate and a population-based design. All
women ≥20 years in the county of Nord-Trøndelag in
Norway were invited, in contrast to many other studies
on UI only focusing on elderly or other limited age-
groups. The study population of Nord-Trøndelag is
regarded to be representative of the female population
of Norway, and we can assume that it gives representa-
tive knowledge about a western, female population. The
questions about UI, anxiety and depression were part of
a questionnaire covering many medical topics, and this
may reduce the risk of underreporting because of em-
barrassment and overreporting because of eagerness to
tell. The scales for both UI, depression and anxiety are
well validated. The UI questions are based on the
Table 3 Odds ratios (ORs) for urinary incontinence (UI) (dependent variable) for persons with high anxiety score- and for persons
with high depression-score (HADS-A and HADS-D ≥ 8, respectively) versus normal anxiety-score and normal depression-score (HADS-
A and HADS-D < 8, respectively) (independent variables). ORs for the different drug groups by different volume (DDD) of drug use.
N = 21,803
Anxiety (HADS-A ≥ 8) Depression (HADS-D ≥ 8)
OR * OR** OR* OR**
Reference (HADS-A/−D < 8) 1.00 1.00 1.00 1.00
Any UI 1.48 (1.36–1.60) 1.48 (1.36–1.61) 1.58 (1.42–1.76) 1.55 (1.39–1.73)
Antidepressants (n = 1947) Low DDD (n = 866) 1.10 (0.94–1.30) 1.12 (0.95–1.32)
Medium DDD (n = 684) 1.30 (1.08–1.55) 1.31 (1.09–1.56)
High DDD (n = 397) 1.36 (1.08–1.71) 1.40 (1.12–1.77)
Opioid analgesics (n = 1697) Low DDD (n = 674) 0.80 (0.67–0.97) 0.80 (0.66–0.97)
Medium DDD (n = 678) 1.00 (0.83–1.20) 1.00 (0.83–1.20)
High DDD (n = 345) 1.08 (0.83–1.40) 1.08 (0.83–1.41)
Other analgesics (n = 1412) Low DDD (n = 417) 0.88 (0.69–1.11) 0.88 (0.69–1.11)
Medium DDD (n = 744) 0.98 (0.82–1.17) 0.99 (0.83–1.18)
High DDD (n = 251) 1.18 (0.88–1.58) 1.15 (0.86–1.54)
Antiepileptic drugs (n = 393) Low DDD (n = 156) 0.86 (0.58–1.26) 0.85 (0.58–1.26)
Medium DDD (n = 165) 1.21 (0.85–1.73) 1.23 (0.86–1.75)
High DDD (n = 72) 1.13 (0.67–1.92) 1.13 (0.67–1.92)
Antiparkinson drugs (n = 95) Low DDD (n = 36) 1.18 (0.55–2.46) 1.18 (0.56–2.50)
Medium DDD (n = 40) 1.35 (0.68–2.92) 1.28 (0.62–2.70)
High DDD (n = 19) 2.64 (1.02–6.85) 2.47 (0.94–6.45)
Antipsychotic drugs (n = 379) Low DDD (n = 153) 1.38 (0.96–1.98) 1.40 (0.98–2.01)
Medium DDD (n = 143) 0.97 (0.66–1.44) 0.97 (0.66–1.44)
High DDD (n = 83) 1.14 (0.69–1.89) 1.15 (0.70–1.90)
Anxiolytic drugs (n = 1172) Low DDD (n = 449) 0.89 (0.71–1.11) 0.94 (0.75–1.17)
Medium DDD (n = 485) 0.80 (0.64–1.00) 0.86 (0.69–1.07)
High DDD (n = 238) 0.64 (0.45–0.91) 0.67 (0.48–0.95)
Hypnotic and sedative drugs (n = 2175) Low DDD (n = 930) 0.96 (0.82–1.13) 0.99 (0.84–1.15)
Medium DDD (n = 827) 0.79 (0.66–0.94) 0.80 (0.67–0.95)
High DDD (n = 418) 1.00 (0.79–1.28) 1.02 (0.80–1.30)
*Adjusted for age, BMI, parity, diabetes, asthma, myocardial infarction and cerebral stroke, chronic pain, rheumatoid arthritis, use of urologic medication and use
of estrogen replacement medication. ** Adjusted for the factors* and in addition psychotropic drugs. DDD: defined daily dose
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definitions from International Continence Society [19],
and includes information making it possible to
categorize for both UI type and UI severity. The severity
index is well validated [20, 21]. The HADS is widely
used in population-based surveys, and the cut-off of 8
has been found to match well with clinically diagnosed
anxiety and depression according to DSM-III/IV and
ICD-8/9 diagnostic criteria [24]. NorPD contains all dis-
pensed prescriptions for all the women included in the
study, and thus reduces the number of missing individ-
uals in the analyses. It has been hypothesized in some
studies that urgency is part of a central sensitization that
also is an explanation-model for chronic pain [30]. In
this study we adjusted for chronic pain and for medica-
tion used for it.
Limitations of the study include that questionnaires
were returned by mail, with potentially lower participa-
tion rate of persons with largest symptom load, e.g. de-
pressed persons. Many of the invited persons in HUNT3
did not come to the screening station or did not return
Q1, representing a possible selection bias. Even if HADS
is validated as a good instrument for assessing symptom
load, it is not a diagnostic tool. A possible bias is also
that NorPD only gives information about dispensed pre-
scriptions, not actual use. We had no available informa-
tion about socioeconomic status, such as income and
work. These factors are related to anxiety and depres-
sion, but in most studies not to UI, and they are there-
fore not regarded as confounders. However, a possible
impact on our results cannot be excluded, and this may
represent a limitation of the study.
The associations between anxiety and UI and depres-
sion and UI, especially urgency and mixed type, corres-
pond well with earlier cross-sectional studies [1, 31]. In
a population-based survey of 3536 women, major de-
pression was associated with severe UI [2]. Other cross-
sectional studies have also shown associations, but the
prevalence of UI, depression, and anxiety vary due to dif-
ferent definitions of UI and different cut-offs and defini-
tions of anxiety and depression [32–35]. In a recent
study, UI during and after pregnancy was associated with
postpartum depression, OR 3.81 (1.57–9.25) [36]. In our
previously conducted cross-sectional study of middle-
aged women, we found ORs for anxiety and depression
of 1.59 (1.36–1.86) and 1.64 (1.32–2.04), respectively,
among women with any UI compared to continent
women [3]. For severe UI, the ORs for anxiety and de-
pression were 2.30 and 2.14, respectively. The results in
the present study thus correspond well with this, but we
now also demonstrate an increasing strength of the asso-
ciation by increasing severity of the HADS-A- and
HADS-D-score. As far as we know, this is the first study
Table 4 Prevalence of and odds ratio for urinary incontinence (UI) for women with and without anxiety and depression, and
women with anxiety and depression using anxiolytics or antidepressants compared to the women with anxiety and depression not
using anxiolytics or antidepressants. P-values by chi-quadrat test
n % P Unadjusted OR Adjusteda OR
Anxiety (n = 21,511) < 0.001
HADS-A < 8 4922 27.6 1.00 (Ref.) 1.00 (Ref.)
HADS-A 8–10.9 827 34.6 1.39 (1.27–1.52) 1.42 (1.29–1.56)
HADS-A≥ 11 498 37.8 1.59 (1.42–1.79) 1.59 (1.40–1.81)
HADS-A ≥ 8 (n = 3705)
Without use of antidepressant 1008 34.4 0.001 1.00 (Ref.) 1.00 (Ref.)
With use of antidepressant 317 40.9 1.32 (1.12–1.55) 1.11 (0.93–1.34)
Without use of anxiolytic 1138 35.9 0.72 1.00 (Ref.) 1.00 (Ref.)
With use of anxiolytic 187 35.1 0.97 (0.80–1.17) 0.80 (0.64–0.99)
Depression (n = 21,545) 21,545 < 0.001
HADS-D < 8 5504 28.0 1.00 (Ref.) 1.00 (Ref.)
HADS-D 8–10.9 562 39.3 1.66 (1.49–1.86) 1.52 (1.35–1.72)
HADS-D≥ 11 195 43.7 2.00 (1.65–2.42) 1.79 (1.46–2.21)
HAD-D ≥ 8 (n = 1877)
Without use of antidepressant 556 39.2 0.08 1.00 (Ref.) 1.00 (Ref.)
With use of antidepressant 201 43.8 1.21 (0.98–1.50) 1.08 (0.85–1.37)
Without use of anxiolytic 648 40.5 0.76 1.00 (Ref.) 1.00 (Ref.)
With use of anxiolytic 109 39.5 0.96 (0.74–1.25) 0.85 (0.63–1.14)
aAdjusted for age, BMI and parity, diabetes, asthma, myocardial infarction and cerebral stroke. Use of drugs is defined as dispensed prescription during the
last 6 months
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investigating the association for different severity grades
of both UI, anxiety, and depression.
Longitudinal studies have shown an association be-
tween anxiety and depression at baseline and incident
UI. UI at baseline is either not, or weaker, associated
with incident anxiety and depression [6, 7]. One longitu-
dinal, population-based study found that UI with
condition-specific functional loss predicted incident anx-
iety disorder [37]. In one study, incontinent women with
depression reported a greater functional loss related to
their UI than women with UI without depression. Pa-
tients with UI and depression also rated their UI as more
severe and had greater quality of life impairment [5].
However, the longitudinal studies give stronger support
for depression and anxiety leading to UI than UI leading
to depression and anxiety.
There are both psychological and biological explan-
ation models for the associations between anxiety/de-
pression and UI. Living with a condition associated with
shame, loss of control, unpredictability and decreased
quality of life, may lead to psychological stress, anxiety
and depression symptoms [35].
Biological theories for the association between anxiety/
depression and UI are linked to the serotonergic and
noradrenergic systems. Dysregulation of 5-HT and NA
in the brain is strongly associated with depression and
anxiety. Serotonergic activity inhibits voiding, by inhibit-
ing the parasympathetic input to the bladder and enhan-
cing the efferent control of the urethral outlet. Low
levels of 5-HT and NA in the CNS could therefore lead
to UI [12]. Peripherally, stimulation of the 5-HT4 recep-
tors in the bladder detrusor, may cause detrusor over-
activity and potentially urgency UI. This could be one
reason for the association between use of antidepres-
sants and higher prevalences of UI [14, 38].
Different psychotropics interfere in these pathways
and earlier studies have investigated a possible associ-
ation with UI. One study found a relative risk (RR) of
1.9 for UI during use of SSRI [14]. Another study found
much higher prevalence of UI among antidepressant
users (64%) than in the control group (33%) [26]. There
has been some evidence for an association between ben-
zodiazepines and UI [28] and between antiepileptics and
UI [27]. Parkinson disease can cause bladder dysfunction
and incontinence [39], but there is lack of studies on the
effect of antiparkinson-drugs on UI.
The association between the use of psychotropics and
UI has previously been investigated in the same data ma-
terial from HUNT3, and the selection of drugs in our
model were chosen partly based on the results in this
study [16]. Mauseth et al. found adjusted associations
between use of SSRIs and UI and between use of lamo-
trigine and UI, with ORs 1.52 and 2.73, respectively, for
two or more prescriptions during the last 6 months.
They also found an association between one dispensed
antipsychotic during the last 6 months and UI with OR
1.91, not significant for two or more dispensed prescrip-
tions. They did not find any associations between benzo-
diazepines or zopiclone/zolpidem and UI. The results
for lamotrigin are uncertain, however, because of very
few women using this drug. For SSRIs, adjustments for
high score on HADS-D in the association did not change
the OR considerably. This could indicate that there is an
independent association between the drug and UI. Like
Mauseth et al., we also found an independent association
between antidepressants and UI. However, the associ-
ation was not present when the women with depression
or anxiety using antidepressants were compared with
women with these conditions not using antidepressants.
Use of anxiolytic medication among patients with anx-
iety seems to give a small decrease in prevalence of UI.
One other study found an association between atypical
antipsychotics and lower urinary tract symptoms (LUTS)
[27]. Our study did not support such association.
Conclusions
Anxiety, depression, and UI are common conditions and
share hormonal and neurological pathways, where also
psychotropic drugs, especially antidepressants, act. There
is therefore a biological substrate behind the observed
associations in this field. Our study expands the cross-
sectional evidence that anxiety and depression are asso-
ciated with all types of UI in women, with increasing
strength of the association by increasing severity of the
conditions. Antidepressant drugs seem to have an inde-
pendent association with UI, but the associations be-
tween UI and anxiety/depression were not influenced by
use of any psychotropic drug.
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